Institution
Misericordia University
Education•Dallas, Pennsylvania, United States•
About: Misericordia University is a education organization based out in Dallas, Pennsylvania, United States. It is known for research contribution in the topics: Population & Occupational therapy. The organization has 712 authors who have published 831 publications receiving 18730 citations. The organization is also known as: College Misericordia.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Planning for psychometric testing through design and reducing nonrandom error in measurement will add to the reliability and validity of instruments and increase the strength of study findings.
Abstract: Purpose: To review the concepts of reliability and validity, provide examples of how the concepts have been used in nursing research, provide guidance for improving the psychometric soundness of instruments, and report suggestions from editors of nursing journals for incorporating psychometric data into manuscripts. Methods: CINAHL, MEDLINE, and PsycINFO databases were searched using key words: validity, reliability, and psychometrics. Nursing research articles were eligible for inclusion if they were published in the last 5 years, quantitative methods were used, and statistical evidence of psychometric properties were reported. Reports of strong psychometric properties of instruments were identified as well as those with little supporting evidence of psychometric soundness. Findings: Reports frequently indicated content validity but sometimes the studies had fewer than five experts for review. Criterion validity was rarely reported and errors in the measurement of the criterion were identified. Construct validity remains underreported. Most reports indicated internal consistency reliability (α) but few reports included reliability testing for stability. When retest reliability was asserted, time intervals and correlations were frequently not included. Conclusions: Planning for psychometric testing through design and reducing nonrandom error in measurement will add to the reliability and validity of instruments and increase the strength of study findings. Underreporting of validity might occur because of small sample size, poor design, or lack of resources. Lack of information on psychometric properties and misapplication of psychometric testing is common in the literature.
1,460 citations
••
University of Cologne1, Misericordia University2, University Hospital of Lausanne3, Radboud University Nijmegen Medical Centre4, Pasteur Institute5, Necker-Enfants Malades Hospital6, Katholieke Universiteit Leuven7, Hacettepe University8, Statens Serum Institut9, Boston Children's Hospital10, Carlos III Health Institute11, University of Strasbourg12, University of Liverpool13, University of Copenhagen14, Innsbruck Medical University15, National and Kapodistrian University of Athens16, Manchester Academic Health Science Centre17, University of Genoa18, University of Würzburg19
TL;DR: This part of the EFISG guidelines focuses on non-neutropenic adult patients, and liposomal amphotericin B and voriconazole are supported with moderate, and fluconazole with marginal strength for the targeted initial treatment of candidaemia.
1,011 citations
••
TL;DR: To improve survival, combined treatment with 2 or more drugs with in vitro activity against the isolate, especially those also including a carbapenem, may be more effective than active monotherapy.
Abstract: Background The spread of Klebsiella pneumoniae (Kp) strains that produce K. pneumoniae carbapenemases (KPCs) has become a significant problem, and treatment of infections caused by these pathogens is a major challenge for clinicians. Methods In this multicenter retrospective cohort study, conducted in 3 large Italian teaching hospitals, we examined 125 patients with bloodstream infections (BSIs) caused by KPC-producing Kp isolates (KPC-Kp) diagnosed between 1 January 2010 and 30 June 2011. The outcome measured was death within 30 days of the first positive blood culture. Survivor and nonsurvivor subgroups were compared to identify predictors of mortality. Results The overall 30-day mortality rate was 41.6%. A significantly higher rate was observed among patients treated with monotherapy (54.3% vs 34.1% in those who received combined drug therapy; P = .02). In logistic regression analysis, 30-day mortality was independently associated with septic shock at BSI onset (odds ratio [OR]: 7.17; 95% confidence interval [CI]: 1.65-31.03; P = .008); inadequate initial antimicrobial therapy (OR: 4.17; 95% CI: 1.61-10.76; P = .003); and high APACHE III scores (OR: 1.04; 95% CI: 1.02-1.07; P Conclusions KPC-Kp BSIs are associated with high mortality. To improve survival, combined treatment with 2 or more drugs with in vitro activity against the isolate, especially those also including a carbapenem, may be more effective than active monotherapy.
861 citations
••
TL;DR: Analysis of all outcome measures, including OS, confirm the benefit of adding R to CVP in the front-line treatment of FL, and FLIPI retains a strong predictive power for TTP in the presence of the trial treatment effect.
Abstract: Purpose To compare the long-term outcome of patients with previously untreated follicular lymphoma (FL) needing therapy, after treatment with cyclophosphamide, vincristine and prednisone (CVP) versus CVP plus rituximab (R-CVP) and to evaluate the predictive value of known prognostic factors after treatment with R-CVP Patients and Methods Patients with previously untreated CD20-positive stage III/IV FL were randomly assigned to eight cycles of R-CVP (n 159) or CVP alone (n 162) The median follow-up period was 53 months Results The primary end point—time to treatment failure (TTF), which included patients without a response after four cycles as an event—was significantly prolonged in patients receiving R-CVP versus CVP (P 0001) Improvements in all other end points, including overall and complete response rates (P 0001), time to progression (TTP; P 0001), response duration (P 0001), time to next antilymphoma treatment (P 0001), and overall survival (OS; P 029; 4-year OS: 83% v 77%;) were achieved with R-CVP versus CVP alone Univariate analyses demonstrated an improvement in TTP with R-CVP versus CVP irrespective of the Follicular Lymphoma International Prognostic Index (FLIPI) subgroup, the International Prognostic Index (IPI) subgroup, baseline histology, and the presence or absence of B symptoms or bulky disease By multivariate analysis, FLIPI retains a strong predictive power for TTP in the presence of the trial treatment effect Conclusion Analysis of all outcome measures, including OS, confirm the benefit of adding R to CVP in the front-line treatment of FL J Clin Oncol 26:4579-4586 © 2008 by American Society of Clinical Oncology
555 citations
••
University of Queensland1, University of Sydney2, Westmead Hospital3, University of Genoa4, National and Kapodistrian University of Athens5, St. Vincent's Health System6, Children's Hospital Los Angeles7, University of Southern California8, Misericordia University9, Claude Bernard University Lyon 110, Paris Diderot University11, Monash University12, University of Hamburg13, Medical University of Vienna14, Ghent University Hospital15
TL;DR: Routine TDM is recommended to be performed for aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole in critically ill patients.
Abstract: This Position Paper aims to review and discuss the available data on therapeutic drug monitoring (TDM) of antibacterials, antifungals and antivirals in critically ill adult patients in the intensive care unit (ICU). This Position Paper also provides a practical guide on how TDM can be applied in routine clinical practice to improve therapeutic outcomes in critically ill adult patients.
Literature review and analysis were performed by Panel Members nominated by the endorsing organisations, European Society of Intensive Care Medicine (ESICM), Pharmacokinetic/Pharmacodynamic and Critically Ill Patient Study Groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID), International Association for Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) and International Society of Antimicrobial Chemotherapy (ISAC). Panel members made recommendations for whether TDM should be applied clinically for different antimicrobials/classes. TDM-guided dosing has been shown to be clinically beneficial for aminoglycosides, voriconazole and ribavirin. For most common antibiotics and antifungals in the ICU, a clear therapeutic range has been established, and for these agents, routine TDM in critically ill patients appears meritorious. For the antivirals, research is needed to identify therapeutic targets and determine whether antiviral TDM is indeed meritorious in this patient population. The Panel Members recommend routine TDM to be performed for aminoglycosides, beta-lactam antibiotics, linezolid, teicoplanin, vancomycin and voriconazole in critically ill patients. Although TDM should be the standard of care for most antimicrobials in every ICU, important barriers need to be addressed before routine TDM can be widely employed worldwide.
438 citations
Authors
Showing all 718 results
Name | H-index | Papers | Citations |
---|---|---|---|
Matteo Bassetti | 69 | 610 | 20264 |
Luigi P. Badano | 65 | 405 | 39313 |
Francesco Zaja | 58 | 276 | 11251 |
Pierluigi Viale | 56 | 403 | 11973 |
Fabio Puglisi | 43 | 298 | 8354 |
Salvatore De Vita | 42 | 180 | 6320 |
Fabio Barbone | 42 | 205 | 6008 |
Gian Luigi Gigli | 41 | 240 | 5663 |
Luca Quartuccio | 41 | 233 | 5285 |
Gian Carlo Di Renzo | 41 | 183 | 5653 |
Fausto Roila | 39 | 163 | 6647 |
John S. Lambert | 38 | 195 | 4739 |
Elda Righi | 37 | 159 | 5568 |
Federico Pea | 37 | 231 | 6059 |
Carlo Tascini | 36 | 236 | 4825 |